Mural Oncology wants to paint a new picture in IL-2 after Alkermes spinout
高管变更
Preview
来源: FierceBiotech
Alkermes announced the plan to separate into two a year ago, with a spinout taking on the oncology work and the legacy company continuing in neuroscience.
Mural Oncology, Alkermes’ cancer spinoff, has officially landed with $275 million in funding and a mission to develop an interleukin-2 (IL-2) candidate for solid tumors.
Alkermes announced the plan to separate into two a year ago, with a spinout taking on the oncology work and the legacy company continuing in neuroscience.
The new spinout is centered around nemvaleukin alfa, which is going through two potentially registrational trials with readouts expected in the first quarter of 2025, according to a Wednesday press release. The therapy is an engineered IL-2 cytokine that Mural hopes will expand the therapeutic benefits of high-dose recombinant human IL-2 agents, which are commonly used for several types of solid tumors, without the usual toxicities.
Nemvaleukin is being tested in mucosal melanoma alone and in platinum-resistant ovarian cancer in combination with Merck & Co.’s Keytruda. The spinout also has a handful of discovery-stage programs in IL-18 and IL-12 for proinflammatory cytokines.
Top-line results for both nemvaleukin trials are expected in the first quarter of 2025. Mural also intends to declare other product candidates from the discovery-stage programs in 2024.
Leading the new company is Caroline Loew, Ph.D., who previously held the top role at Glympse Bio and before that served as head of R&D strategy and planning at Bristol Myers Squibb. Vicki Goodman, M.D., will fill the role of chief medical officer. She was previously executive vice president, product development and medical affairs, and chief medical officer at Exelixis.
Detailed financial terms were not provided, but Mural will have the $275 million in committed funding, which is projected to provide a cash runway into the first quarter of 2025.
Meanwhile, Alkermes has continued with commercializing schizophrenia and bipolar disorder drug Lybalvi.
更多内容，请访问原始网站
文中所述内容并不反映新药情报库及其所属公司任何意见及观点，如有版权侵扰或错误之处，请及时联系我们，我们会在24小时内配合处理。
来和芽仔聊天吧
立即开始免费试用!
智慧芽新药情报库是智慧芽专为生命科学人士构建的基于AI的创新药情报平台，助您全方位提升您的研发与决策效率。
立即开始数据试用!
智慧芽新药库数据也通过智慧芽数据服务平台，以API或者数据包形式对外开放，助您更加充分利用智慧芽新药情报信息。